close

Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide. The company develops products that treat gastrointestinal infections and related diseases. Its two late-stage anti-infective product candidates include Fidaxomicin, the lead product candidate and an antibiotic that is in second Phase III registration trial for the treatment of clostridium difficile-infections; and Prulifloxacin, a prodrug in the fluoroquinolone class of antibiotics, which completed second Phase III trials for the treatment of infectious diarrhea in travelers. It also develops OP-1068/CEM-101, an antibiotic for the treatment of upper and lower respiratory tract infections; OPT-88, a disease-modifying intra-articular, or within the cavity of a joint, therapy for osteoarthritis; OPT-822, a carbohydrate-based cancer immunotherapy for the treatment of metastatic breast cancer; and an OPopS drug discovery platform. The company has a collaborative research and development, and license agreement with Cempra Pharmaceuticals, Inc. to discover, develop, and commercialize drugs based on macrolide and ketolide compounds. Optimer Pharmaceuticals was founded in 1998 and is based in San Diego, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	12.94
Volume	704709
Volume Avg	529395
52 Week High	17.95
52 Week Low	6.81
PE	75.18
PE (group average)	N/A
EPS Year	0.17
EPS change Q/Q	-1000%
EPS change Q/Q Yr ago	-1000%
EPS change Q/Q next Q est	-1000%
EPS change Y/Y	1000%
REV change Q/Q	34550%
REV change Q/Q Yr ago	23000%
EPS next Q est	-0.54
EPS next Y est	-1.07
Divident Annual	0.00
Dividend Yield	0%